Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy.
According to one popular theory, hepatic encephalopathy (HE) is partly caused by an imbalance in plasma amino acid levels. The Fischer's ratio between branched chain amino acids (BCAAs) and aromatic amino acids (AAAs) correlates with the degree of HE; the lower Fischer's ratio, the higher the grade of HE. Extra-corporeal liver support systems, like MARS(R)-albumin dialysis (Molecular Adsorbents Recirculating System), can improve HE. The MARS(R) system uses a hyperosmolar albumin circuit to remove both water-soluble and albumin-bound substances. Plasma levels of neuroactive amino acids were analyzed in 82 consecutive patients with life-threatening liver failure admitted to our ICU. All patients fulfilled our indications for MARS treatment and most also fulfilled the criteria for liver transplantation (LTx). In patients with acute liver failure (ALF), as compared to those with acute decompensation of chronic liver failure (AcOChr), levels of leucine and isoleucine were significantly higher before MARS(R) treatment. In all patients, before MARS(R) treatment the higher the grade of HE grade the lower was the Fischer's ratio and higher were the levels of inhibitory neuroactive amino acids. During MARS(R) treatments the Fischer's ratio increased, and the grade of HE decreased. The increase in Fischer's ratio was mainly due to the decrease in AAAs. The plasma levels of neuroactive amino acids, methionine, glutamine, glutamate, histidine and taurine decreased during MARS(R)-treatment. In this study MARS(R)-albumin dialysis had a favorable effect on the plasma amino acid profile of patients with HE.
Koivusalo
Anna-Maria
AM
Department of Anaesthesiology and Intensive Care, Helsinki University Hospital, P.O. Box 263, Helsinki, Finland. anna-maria.koivusalo@hus.fi
Teikari
Taru
T
Höckerstedt
Krister
K
Isoniemi
Helena
H
D000328:Adult; D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D000596:Amino Acids / Q000097:blood* / Q000145:classification; D003131:Combined Modality Therapy; D003956:Dialysis / Q000379:methods*; D015314:Dialysis Solutions / Q000737:chemistry / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000295:instrumentation / Q000379:methods; D006501:Hepatic Encephalopathy / Q000097:blood / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D017114:Liver Failure, Acute / Q000097:blood / Q000150:complications / Q000628:therapy*; D019164:Liver, Artificial; D008875:Middle Aged; D009994:Osmolar Concentration; D012720:Severity of Illness Index; D016060:Sorption Detoxification / Q000379:methods; D016896:Treatment Outcome
D000418:Albumins; D000596:Amino Acids; D015314:Dialysis Solutions
Duodecim. 2002;118(6):649-50
12233010
Surgery. 1976 Jul;80(1):77-91
818729
J Neurochem. 1990 Jul;55(1):222-9
1693945
Science. 1977 Mar 25;195(4284):1356-8
14400
Transpl Int. 2005 Jan;17(11):717-23
15580335
Atherosclerosis. 1995 Jun;115(2):217-24
7661880
Transplant Proc. 2001 Sep;33(6):2897-9
11543780
Liver. 2002;22 Suppl 2:35-9
12220301
Liver Transpl. 2000 May;6(3):277-86
10827226
Int J Biochem Cell Biol. 2003 Aug;35(8):1175-81
12757755
Hepatology. 1994 Feb;19(2):329-38
8294090
J Hepatol. 2003 Oct;39(4):522-7
12971961
J Neurochem. 1998 May;70(5):1998-2003
9572285
Gastroenterol Jpn. 1982 Apr;17(2):117-24
6286400
Pharmacol Rev. 1997 Sep;49(3):253-78
9311023
Neurochem Res. 1998 May;23(5):635-44
9566601
Neurochem Res. 1984 Sep;9(9):1309-21
6150451
Metab Brain Dis. 1996 Jun;11(2):165-73
8776718
Liver Int. 2003;23 Suppl 3:5-9
12950954
Liver Transpl. 2002 Nov;8(11):1055-62
12424720
Scand J Gastroenterol. 2004 Oct;39(10):974-80
15513337
Surgery. 2001 Aug;130(2):354-62
11490371
Artif Organs. 1999 Apr;23(4):319-30
10226696
Gastroenterology. 1977 Mar;72(3):483-7
832796
Liver Transpl. 2001 Aug;7(8):709-12
11510016
J Neurol Sci. 1999 Nov 30;170(2):138-46
10617392
Acta Anaesthesiol Scand. 2003 Oct;47(9):1145-50
12969110
Metab Brain Dis. 1989 Sep;4(3):169-76
2796871